Exagen Inc. (NYSE:XGN) – Analysts at Cantor Fitzgerald lowered their FY2019 earnings per share (EPS) estimates for shares of Exagen in a note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst C. Bijou now anticipates that the company will earn ($1.96) per share for the year, down from their previous estimate of ($1.63). Cantor Fitzgerald has a “Overweight” rating and a $18.00 price target on the stock. Cantor Fitzgerald also issued estimates for Exagen’s FY2020 earnings at ($1.56) EPS.
Several other research firms have also commented on XGN. Cowen initiated coverage on shares of Exagen in a research report on Monday, October 14th. They set an “outperform” rating and a $17.00 price target for the company. William Blair initiated coverage on shares of Exagen in a research report on Monday, October 14th. They set an “outperform” rating for the company.
Several institutional investors and hedge funds have recently bought and sold shares of XGN. Perkins Capital Management Inc. acquired a new position in shares of Exagen during the third quarter valued at about $1,355,000. Teacher Retirement System of Texas acquired a new position in shares of Exagen during the third quarter valued at about $310,000. Russell Investments Group Ltd. acquired a new position in shares of Exagen during the third quarter valued at about $967,000. Finally, Dean Capital Investments Management LLC acquired a new position in shares of Exagen during the third quarter valued at about $221,000.
In related news, major shareholder Bio-Exagen L.P. H.I.G. acquired 859,897 shares of the business’s stock in a transaction dated Thursday, September 19th. The shares were purchased at an average price of $17.24 per share, for a total transaction of $14,824,624.28.
Exagen Company Profile
Exagen Inc operates as a commercial-stage diagnostics company, develops and markets products for the diagnosis, prognosis, and monitoring of patients affected by autoimmune rheumatic diseases (ARDs). Its lead product includes Avise SLE+CT, a proprietary diagnostic test that provides an enhanced solution for patients with a range of ARDs, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome, and scleroderma, as well as other disorders, including fibromyalgia.
Further Reading: Investing in Dividend Stocks
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.